Vitiligo

Researchers stated the dual-action therapy could offer a promising approach to treat progressive non-segmental vitiligo.

VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.

Learn more about the in-depth topics covered in the October 2024 vitiligo supplement of Dermatology Times.

In a Dermatology Times Case-Based Roundtable event, Pearl E. Grimes, MD, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

In a Dermatology Times Case-Based Roundtable event, Ted Lain, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

Studies show conflicting serum levels of zinc and copper in vitiligo patients, indicating a need for further research.

In a Dermatology Times Case-Based Roundtable event, Chesahna Kindred, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib cream.

Investigators noted that further research is needed to monitor the prevalence of cardiovascular disease in patients with vitiligo.

Panelists discuss how treatment cycling strategies and optimal use of ruxolitinib can enhance the management of vitiligo, providing key takeaways for clinical practice.

In a Dermatology Times Case-Based Roundtable event, Andrew Alexis, MD, MPH, FAAD, reviewed 3 cases of patients with vitiligo treated with ruxolitinib cream.

A review examined how vitiligo treatments aim to restore melanocyte function through grafting, phototherapy, immune regulation, antioxidants, and stem cell research.

Researchers behind the review suggested that future research should prioritize large-scale trials to confirm abrocitinib's long-term safety and efficacy in various skin disorders.

Researchers found that MBEHQ treatment increased oxidative stress and proinflammatory cytokines IL-1β and IL-18 in patients with vitiligo.

Catch up on the latest news on vitiligo advancements in 2024.

The study is actively recruiting participants at multiple sites across the US.

The study showed significant improvement in repigmentation with silymarin, with patients of different sexes benefiting equally, though monthly differences were not significant.

The 83-year-old patient was being treated for mycosis fungoides.

42 studies with 1027 cases evaluated drugs like bimatoprost and apremilast for vitiligo.

Researchers identified KLB and EIF3C as potential biomarkers for vitiligo and AA, offering new targets for early diagnosis and treatment.

Learn more about the in-depth topics covered in the August 2024 supplement of Dermatology Times.

At the conclusion of their roundtable event, Rocco Serrao, MD, FAAD; Latanya Benjamin, MD, FAAD; and Anthony Nuara, MD, PhD, discuss final considerations for tailoring vitiligo treatment plans.

Anthony Nuara, MD, PhD, reviewed a case study of a 32-year-old professional makeup artist who was concerned about her depigmented patches affecting her livelihood.

Latanya Benjamin, MD, FAAD, reviewed a case study of a 35-year-old woman with a 10-year history of vitiligo and concomitant atopic dermatitis

Rocco Serrao, MD, FAAD, reviewed a case study of a 20-year-old man with segmental vitiligo and the psychological impact of his vitiligo.

The findings highlight the need for diverse genetic studies to understand their broader impact on autoimmune diseases.